Skip to content
Screener

Balchem BCPC Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Elanco Animal Health Inc. logo
Elanco Animal Health Inc.ELAN
$1B
Westlake logo
WestlakeWLK
$50M0.0%
Archer Daniels Midland logo
Archer Daniels MidlandADM

Other financials

Income statement

See full
Revenue$270.7M+8.1%
Gross profit$101.1M+14.6%
Operating income$55.6M+9.0%
Net income$40.3M+8.7%
EPS (diluted)$1.25+10.6%

Balance sheet

See full
Cash & equivalents$72.9M+46.0%
Total debt$37.4M-1.7%
Total equity$1.3B+6.3%
Total assets$1.7B+4.7%

Cash flow

See full
Operating cash flow$40.1M+9.9%

Valuation

See full
Market cap$5.65B+9.5%
Enterprise value$5.61B+9.4%
P/E35.7×-0.4×
P/S5.3×+0.1×

Profitability

See full
Gross margin36.3%+0.7pp
Operating margin20.2%+0.3pp
Net margin15%+0.8pp
FCF margin14.9%

Returns & leverage

See full
Return on equity12.7%+0.7pp
Debt / equity0.0×
Current ratio2.5×+0.1×

Where this comes from

Reported directly by Balchem in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Balchem’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:33 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000009326-26-000018
Assets / Current assets:March 31, 2026 / (unaudited)December 31, 2025
Total liabilities408,626428,839
Commitments and contingencies (Note 15)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,128,526 and 32,058,121 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively2,1432,139
Additional paid-in capital89,54392,331
Retained earnings1,161,6811,121,396
Accumulated other comprehensive income31,74941,547

Item 1. Financial Statements (unaudited)

FAQ

What is Balchem's preferred stock, shares authorized?
Balchem (BCPC) reported preferred stock, shares authorized of $2M in Q1 2026.
How has Balchem's preferred stock, shares authorized changed year-over-year?
Balchem's preferred stock, shares authorized decreased by 0.0% year-over-year, from $2M to $2M.
What is the long-term trend for Balchem's preferred stock, shares authorized?
Over 5 years (2020 to 2025), Balchem's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $2M to $2M.

Ask your AI about Balchem's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude